- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Medicus Pharma Ltd: Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Novel Study in Acute Urinary Retention | 174 | GlobeNewswire (Europe) | PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 04.07. | New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell's Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group | 4.517 | ACCESS Newswire | Honoring Economic Freedom and American Capitalism Through Television That Connects Markets, Entrepreneurs, and InvestorsNational Sponsored Broadcast Includes Executive Interviews and Television Commercial... ► Artikel lesen | |
| 22.06. | Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026 | 9 | Benzinga.com | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.06. | Medicus Pharma Ltd: Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 | 7 | GlobeNewswire (USA) | ||
| 15.06. | Medicus Pharma Ltd: Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome | 7 | GlobeNewswire (USA) | ||
| 11.06. | Medicus Pharma submits IND application for endometriosis trial | 3 | Investing.com | ||
| 11.06. | Medicus Pharma Ltd: Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program | 215 | GlobeNewswire (Europe) | PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 08.06. | Medicus Pharma Ltd: Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission | 610 | GlobeNewswire (Europe) | PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 03.06. | Medicus Pharma Ltd: Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome | 321 | GlobeNewswire (Europe) | PHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 28.05. | Medicus Pharma secures up to $22M financing facility | 5 | Investing.com | ||
| 28.05. | Medicus Pharma Ltd: Medicus Pharma Announces $22 Million Non-Dilutive Financing | 692 | GlobeNewswire (Europe) | PHILADELPHIA, May 28, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 27.05. | Medicus Pharma Ltd. - 8-K, Current Report | 6 | SEC Filings | ||
| 16.05. | New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast, Stardust Power, Lost Soldier Oil and Gas, Virtuix Holdings, and Medicus Pharma | 843 | ACCESS Newswire | The show broadcasts as sponsored programming featuring TV commercials from IGC Pharma, Inc. (NYSE American:IGC), NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), Medicus Pharma Ltd. (NASDAQ:MDCX), and DataVault... ► Artikel lesen | |
| 14.05. | Medicus Pharma Ltd. GAAP EPS of -$0.31 | 6 | Seeking Alpha | ||
| 14.05. | Medicus Pharma Ltd: Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | 456 | GlobeNewswire (Europe) | PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 14.05. | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Medicus Pharma reports dose response data from skin cancer study | 11 | Investing.com | ||
| 06.05. | Medicus Pharma Ltd: Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response | 338 | GlobeNewswire (Europe) | PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 29.04. | Medicus Pharma Ltd. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 27.04. | Medicus Pharma Ltd: Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill | 7 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
78 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,850 | +0,78 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| GILEAD SCIENCES | 113,86 | -2,45 % | Big Pharma sucht den nächsten Blockbuster - weshalb Zelltherapien wieder stärker in den Fokus rücken | ||
| ELI LILLY | 1.025,00 | +2,05 % | Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt | ||
| VERTEX PHARMACEUTICALS | 421,30 | +0,08 % | Laufende Fusionskontrollverfahren: Vertex Pharmaceuticals Incorporated, Boston, MA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Crinetics Pharmaceuticals, Inc., San Diego, CA/USA | Datum der Anmeldung:10.07.2026Aktenzeichen:B3-78/26Unternehmen:Vertex Pharmaceuticals Incorporated, Boston, MA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Crinetics Pharmaceuticals, Inc.... ► Artikel lesen | |
| INNOCAN PHARMA | 1,910 | +9,14 % | InnoCan Pharma: Das Signal das jetzt alles ändern könnte: Was hinter dem Kursanstieg wirklich steckt - Was das für Ihr Depot bedeutet | ||
| HAEMATO | 12,900 | 0,00 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| EYEPOINT | 11,300 | +1,80 % | EyePoint, Inc. - 8-K, Current Report | ||
| JAZZ PHARMACEUTICALS | 221,30 | +3,75 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 | View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-august-3-2026-302829880... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 5,300 | -3,64 % | Canaccord reiterates Achieve Life Sciences stock rating on CRL review | ||
| LIGAND PHARMACEUTICALS | 266,00 | +3,91 % | Benchmark erhöht Kursziel für Ligand Pharma nach XOMA-Deal auf 335 $ | ||
| UNITED THERAPEUTICS | 460,30 | -0,75 % | United Therapeutics Buys Thymmune Therapeutics | WASHINGTON (dpa-AFX) - United Therapeutics Corp. (UTHR) on Thursday announced the acquisition of privately held Thymmune Therapeutics for up to $300 million.The transaction includes $140 million... ► Artikel lesen | |
| OPKO HEALTH | 1,060 | +0,95 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 1,260 | 0,00 % | Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review | Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH
17.07.2026 / 17:49 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ROYALTY PHARMA | 50,01 | -0,38 % | Royalty Pharma plc: Royalty Pharma declares third quarter 2026 dividend | NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | XFRA CN2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCATALYST PHARM.INC.DL-001... ► Artikel lesen |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +9,27 % bei einem Aktienkurs von 0,387 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.